Medical News Today: Concerta vs. Adderall: What's the difference?
Concerta and Adderall are both medications that can help treat the symptoms of attention deficit hyperactivity disorder (ADHD). Learn about the differences between them and the possible side effects in this article. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 10, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news
Medical News Today: Ritalin vs. Adderall: What's the difference?
Ritalin and Adderall are different types of stimulant medication that doctors can prescribe to help treat ADHD. Learn about the differences between them and the possible side effects here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 10, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news
Might microdosing psychedelics be safe and beneficial? An initial exploration - Fadiman J, Korb S.
Albert Hoffman suggested that low doses of LSD might be an appropriate alternative to Ritalin. Following this possibility, a systematic exploration of the effects of "microdoses," comprising hundreds of lengthy descriptive reports, was undertaken. Based on... (Source: SafetyLit)
Source: SafetyLit - April 4, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Can delayed/extended-release methylphenidate allow for once daily evening dosing in ADHD?
(Mary Ann Liebert, Inc./Genetic Engineering News) A new three-part study showed that a delayed-release, extended-release form of methylphenidate could be given to adults in the evening with or without food and would not exert any clinically meaningful effect for at least 10 hours after administration. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 2, 2019 Category: International Medicine & Public Health Source Type: news
ANI Pharmaceuticals Announces Two Generic Product Launches
BAUDETTE, Minn., March 27, 2019 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced the launch of 18mg and 27mg Methylphenidate Hydrochloride Extended-Release T... Biopharmaceuticals, Generics, Product Launch ANI Pharmaceuticals, Methylphenidate, Attention Deficit Hyperactivity Disorder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2019 Category: Pharmaceuticals Source Type: news
Childhood methylphenidate treatment predicts antidepressant use during adolescence
(Bar-Ilan University) A new, 12-year longitudinal study, which monitored 6,830 children from early childhood into adolescence, has shown that consistent treatment with MPH-based medications during childhood increases the risk of antidepressant use during adolescence. The study is the first of its kind to examine the connection between children diagnosed with ADHD and prescribed MPH between the ages of six and eight, and future dispensed prescriptions of antidepressants. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 27, 2019 Category: International Medicine & Public Health Source Type: news
Psychosis Risk Varies With ADHD Meds, Still Small
In the study, people who took amphetamines, like Adderall and Vyvanse, seemed to carry a relatively greater risk than the methylphenidates Ritalin and Concerta. (Source: WebMD Health)
Source: WebMD Health - March 21, 2019 Category: Consumer Health News Source Type: news
In Youth With ADHD, New-Onset Psychosis Up With Amphetamines
THURSDAY, March 21, 2019 -- For adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD), new-onset psychosis occurs more often with amphetamine use versus methylphenidate use, according to a study published in the March 21... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 21, 2019 Category: Pharmaceuticals Source Type: news
Young people on amphetamines for ADHD have twice the psychosis risk compared to other stimulants, study says
Teens and young adults with attention deficit-hyperactivity disorder, ADHD, who receive amphetamines such as Adderall for treatment have a higher risk of developing psychosis, compared to those who receive methyphenidates stimulants, such as Ritalin, according to a large new study. (Source: CNN.com - Health)
Source: CNN.com - Health - March 20, 2019 Category: Consumer Health News Source Type: news
Some ADHD Meds Tied to a Higher Psychosis Risk Than Others Some ADHD Meds Tied to a Higher Psychosis Risk Than Others
Amphetamines are associated with a higher psychosis risk than methylphenidate in young patients who take these agents to treat attention deficit hyperactivity disorder.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - March 20, 2019 Category: Primary Care Tags: Psychiatry News Source Type: news
With ADHD, amphetamine has double the psychosis risk of methylphenidate
(Reuters Health) - Children and young adults with attention deficit-hyperactivity disorder (ADHD) who are treated with the stimulants amphetamine or methylphenidate face a small but significant risk of developing psychosis, with amphetamine products twice as likely to spark at problem, researchers say. (Source: Reuters: Health)
Source: Reuters: Health - March 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Popular Spice Rivals Stimulant for ADHD Popular Spice Rivals Stimulant for ADHD
The popular and expensive spice saffron appears to be as effective as the stimulant methylphenidate in treating symptoms in youngsters with ADHD, new research suggests.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 11, 2019 Category: Psychiatry Tags: Psychiatry News Source Type: news
Adhansia XR (Methylphenidate Hydrochloride Extended-release Capsules) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the Treatment of ADHD
STAMFORD, Conn.--(BUSINESS WIRE) March 01, 2019 --Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR (methylphenidate hydrochloride) extended-release capsules... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 1, 2019 Category: Drugs & Pharmacology Source Type: news
Nootropics, or ‘Smart Drugs,’ Are Gaining Popularity. But Should You Take Them?
The idea that a pill can supersize human intelligence is decidedly science fiction. But plenty of real-world researchers and drug-makers are working to develop nootropics: pills, supplements and other substances designed to improve various aspects of cognition.
A rough translation for the word “nootropic” comes from the Greek for “to bend or shape the mind.” And already, there are dozens of over-the-counter (OTC) products—many of which are sold widely online or in stores—that claim to boost creativity, memory, decision-making or other high-level brain functions. Some of the most popular ...
Source: TIME: Health - January 23, 2019 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Drugs Source Type: news
